Latest Breaking News On - Committee for medicinal products human use - Page 2 : comparemela.com

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 rADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura cTTP

Takeda TSE4502NYSETAK today announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has recommended the approval under exceptional circumstances of recombinant ADAMTS13 rADAMTS13 for the treatment of ADAMTS13 deficiency in children and adult patients with cTTP.

United statesKremer hovingaJun saitoVan dorlandThromb haemostTakeda pharmaceutical company limitedExchange commissionJapanese ministry of healthEuropean medicines agencyEuropean commissionTreatment optionsDrug administrationEuropean unionFranchise global program leader at takedaCommittee for medicinal products human usePotentially fatal blood clotting disorder

CStone Pharmaceuticals: CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC

EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demonstrating significant progression-free survival (PFS) and overall survival (OS) benefits of sugemalimab

Jason yangCommittee for medicinal products human useRegulatory agencyEuropean medicines agencyEuropean commissionPrnewswire cstone pharmaceuticalsDrug administrationCentral eastern europeMedicinal productsHuman useExecutive directorLancet oncologyNature cancerIhr portfolio

CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC

EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demonstrating significant progression-free survival (PFS) and.

Jason yangPrnewswire cstone pharmaceuticalsEuropean commissionEuropean medicines agencyCommittee for medicinal products human useDrug administrationRegulatory agencyCentral eastern europeMedicinal productsHuman useExecutive directorLancet oncologyNature cancer

Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union

Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United statesNoord hollandUnited kingdomSouth koreaCity ofMichael levitanChristina renfroeLifespring life sciences communicationEuropean medicines agencyCommittee for medicinal products human useAd hoc expert groupPharming groupExchange commissionPharming groupnvDrug administrationVp investor relations corporate communications

Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesTimothy gilbertSandrine guendoulThomas kudsk larsenHannah kwaghEvan berlandNathalie phamVesna tosicTarik elgoutniFelix lauscherCorentine driancourtDupilumab development programDrug administrationEuropean medicines agencyCommittee for medicinal products human use